• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.

作者信息

Larsson P A, Carlsson G, Gustavsson B, Graf W, Glimelius B

机构信息

Department of Surgery, Ostra sjukhuest, Göteborg University, Sweden.

出版信息

Acta Oncol. 1996;35(2):207-12. doi: 10.3109/02841869609098503.

DOI:10.3109/02841869609098503
PMID:8639317
Abstract

The pharmacokinetics after 20 min intravenous infusion or a 2 min bolus (push) injection of 5-fluorouracil (500 mg/m2) were studied in 14 colorectal cancer patients. Treatment effects and toxicity related to the administration technique of 5-fluorouracil were retrospectively analysed in 198 colorectal cancer patients. The AUC after bolus injection was 6158 +/- 874 micromol/lmin compared to 3355 +/- 428 micromol/lmin after short-time infusion of 5-fluorouracil (p < 0.01). The mean peak-level after bolus injection was 341 +/- 34 microM versus 161 +/- 17 microM after a short-time infusion (p < 0.01). Patients receiving bolus injections had significantly better treatment result (32% partial remission) than patients receiving infusion (10% partial remissions, p < 0.001). Toxic side-effects were more frequently encountered after bolus injection but subjective improvement was also more frequently experienced by these patients. Bolus 5-fluorouracil push injection rather than a short-time infusion appears to be the more efficient administration technique.

摘要

相似文献

1
Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.
Acta Oncol. 1996;35(2):207-12. doi: 10.3109/02841869609098503.
2
Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.晚期结直肠癌患者大剂量注射(2 - 4分钟)与短期(10 - 20分钟)输注5-氟尿嘧啶的比较:一项前瞻性随机试验。北欧胃肠道肿瘤辅助治疗组
Eur J Cancer. 1998 Apr;34(5):674-8. doi: 10.1016/s0959-8049(97)10055-7.
3
Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.晚期结直肠癌中推注氟尿嘧啶与输注氟尿嘧啶联合或不联合顺铂的III期研究。
J Natl Cancer Inst. 1996 May 15;88(10):668-74. doi: 10.1093/jnci/88.10.668.
4
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.交替推注和持续输注5-氟尿嘧啶:一种克服晚期结直肠癌患者对这种氟嘧啶耐药性的策略。
Cytotechnology. 1996;19(3):215-9. doi: 10.1007/BF00744215.
5
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.以一小时静脉输注方式给予5-氟尿嘧啶的药代动力学和药效学效应。
Cancer Chemother Pharmacol. 2001;47(2):117-25. doi: 10.1007/s002800000189.
6
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
J Clin Oncol. 1996 Mar;14(3):729-36. doi: 10.1200/JCO.1996.14.3.729.
7
Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.大剂量5-氟尿嘧啶的药代动力学:剂量、血浆浓度、曲线下面积与毒性之间的关系。
J Chemother. 2005 Jun;17(3):315-20. doi: 10.1179/joc.2005.17.3.315.
8
Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
J Natl Cancer Inst. 1993 Jan 6;85(1):41-4. doi: 10.1093/jnci/85.1.41.
9
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.比较每月低剂量亚叶酸钙和氟尿嘧啶推注与每两个月高剂量亚叶酸钙和氟尿嘧啶推注加持续输注用于晚期结直肠癌的随机试验:一项法国多中心研究。
J Clin Oncol. 1997 Feb;15(2):808-15. doi: 10.1200/JCO.1997.15.2.808.
10
5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.5-氟尿嘧啶分剂量给药;晚期结直肠癌中北欧方案不同给药时间表的I/II期及药代动力学研究
Anticancer Res. 2003 Mar-Apr;23(2C):1789-94.

引用本文的文献

1
Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.金诺芬及其类似物作为治疗结直肠癌的潜在药物。
Cancer Drug Resist. 2022 Jan 4;5(1):1-14. doi: 10.20517/cdr.2021.71. eCollection 2022.
2
9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells.9-ING-41,一种GSK-3β的小分子抑制剂,增强化疗对结肠癌细胞的作用。
Front Pharmacol. 2021 Dec 9;12:777114. doi: 10.3389/fphar.2021.777114. eCollection 2021.
3
Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models.
基于FZD10抗体偶联脂质体的5-氟尿嘧啶控释给药在结直肠癌体外模型中的有效性
Pharmaceutics. 2020 Jul 10;12(7):650. doi: 10.3390/pharmaceutics12070650.
4
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.肿瘤治疗药物监测:国际治疗药物监测和临床毒理学协会关于氟尿嘧啶治疗的建议。
Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11.
5
Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.5-氟尿嘧啶用于复发性室管膜瘤儿童和青年患者的I期研究。
Neuro Oncol. 2015 Dec;17(12):1620-7. doi: 10.1093/neuonc/nov181. Epub 2015 Nov 4.
6
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.PN401、5-氟尿嘧啶和亚叶酸钙用于不可切除或转移性胃腺癌的II期试验:一项西南肿瘤协作组研究
Invest New Drugs. 2006 Nov;24(6):537-42. doi: 10.1007/s10637-006-9244-8.
7
Relationships between body composition parameters and fluorouracil pharmacokinetics.身体成分参数与氟尿嘧啶药代动力学之间的关系。
Br J Clin Pharmacol. 2002 Aug;54(2):131-9. doi: 10.1046/j.1365-2125.2002.01598.x.
8
Can pharmacokinetic monitoring improve clinical use of fluorouracil?药代动力学监测能否改善氟尿嘧啶的临床应用?
Clin Pharmacokinet. 1999 Jun;36(6):391-8. doi: 10.2165/00003088-199936060-00001.